ArticleWiener medizinische Wochenschrift (1946)2025
Monitoring analysis of the use of biosimilar medicines in the Campania region (southern Italy) to support effective and sustainable care.
Article in Wiener medizinische Wochenschrift (1946), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiosimilar drugs offer a valuable opportunity for healthcare systems worldwide, providing significant cost savings and ensuring the same level of effectiveness and safety in the treatment of chronic conditions. These savings can be reinvested into continuous medical innovations.
methodsA search was carried out to assess the use of key biosimilar medications across various therapeutic areas within an Italian health authority that serves a population of over 1 million people. Data on usage, costs, and the number of patients treated were obtained from the company databases. In addition, a comparison with the year 2022 was performed, aiming to identify any increase in the use of biosimilar drugs during 2023.
resultsThe analysis of 2023 revealed that a large majority of the studied active ingredients are administered as biosimilar medications, with only a few exceptions. Resistance remains in the prescription of adalimumab and etanercept, with spending on the originators of close to 3 million euros.
conclusionThe comparison between 2023 and 2022 highlighted the growing adoption of biosimilar medications. This positive trend suggests the potential for achieving full utilization in the near future. Such a result would significantly benefit the national healthcare system and the public, ensuring a healthcare approach that is both effective and sustainable.
Indexed as
Identifiers
40042733What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.